Most cases of non-necrotising scleritis can be successfully treated with non-steroidal antiinflammatory drugs. If these are ineffective, then high-dose systemic corticosteroids, with all their attendant side-effects, are usually required. We have used orbital floor injections of depot steroid in the management of nine patients with non-necrotising scleritis in an attempt to avoid the use of systemic steroids, or to allow the dose of steroids to be reduced while maintaining disease control. A temporary reduction in inflammation was achieved in all cases, which allowed the use of systemic steroids to be avoided altogether in two patients and delayed in the others. Non-steroidal antiinflammatory drugs and systemic corticosteroids remain the mainstay of treatment for non-necrotising scleritis, but orbital floor injections may be a useful adjunct in certain cases.
Scleritis is a potentially serious disorder, which can occur in both young and old patients. Although it can be associated with an underlying collagen disease, many patients are healthy. Pain is a predominant feature of active scleral inflammation, and is the usual presenting complaint.
Patients with anterior diffuse (Fig 1) or nodular, non-necrotising scleritis, and posterior scleritis, can often be treated with non-steroidal anti-inflammatory drugs (NSAIDs), such as flurbiprofen or indomethacin. Necrotising scleritis, however, always requires systemic steroid therapy, sometimes in combination with other systemic immunosuppressive drugs.' Topical steroid therapy can control episcleral inflammation but has no After one or two weeks of treatment the patients were reassessed. If the pain was controlled, and the degree of inflammation reduced, the NSAIDs were continued, and eventually tapered off when the disease process was quiescent. If there was no change, or if the inflammation had increased, then systemic steroids were started in cases of bilateral disease. Patients with unilateral disease, however, received, with informed consent, an orbital floor injection of 40 mg methylprednisolone acetate (Depomedrone). The steroid was mixed with 0-2 ml lignocaine 2%, and administered through the lower lid, at the junction of the inner twothirds and outer one-third.4 The patients were examined again after one or two weeks, and Table 1 . Nine patients received an orbital floor steroid injection. They could be divided into two groups: group A (patients 1-3) in whom NSAIDs were ineffective or could not be tolerated, and in whom systemic steroids had not yet been used; group B (patients 4-9) in whom systemic steroids had been previously used with good effect, but recourse to a high dose was now to be avoided. Seven patients received one injection, one received two, and another three.
In group A the treatment achieved pain control for only four days in one patient and seven days in another. Both required subsequent high-dqse systemic steroid therapy to control the scleral inflammation, instituted two weeks after injection. In the third, although pain was controlled, a large scleral nodule remained unaffected. No steroids were required in this patient, however, as there was now no active inflammation.
In group B only one patient (no. 8) did not require an increase ofsystemic steroids to achieve disease control eventually. The use of high-dose steroids, however, was delayed for five months in one patient and nine months in another. In patient nine the use of orbital floor steroids allowed a dangerously high blood pressure to be satisfactorily controlled before oral steroids were started.
There were no complications from the procedure, which was generally well tolerated by the patient. NSAIDs remain the initial therapy for nonnecrotising scleritis, followed by systemic steroids should the NSAIDs prove to be ineffec-tive. If the use of steroids is temporarily contraindicated, however, or should it prove to be difficult to reduce the minimum controlling steroid dose, then orbital floor steroid should be considered as a useful adjunct.
